CLOs on the Move

Tamer International

www.tamer.com

 
Tamer International is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

QRS Diagnostic

"Founded in 1995 and headquartered in Plymouth, Minnesota, QRS Diagnostic designs and develops software-based medical devices, built into computer cards and USB modules, which cost 25 percent to 50 percent less than traditional device products. ""QRS is"

Hygeia Labs

Hygeia Labs is a Stafford, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bio-Test Laboratory

Bio-Test Laboratory is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Fibertec Inc

Fibertec Inc is a Holt, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.